Satralizumab (a monoclonal antibody that targets the interleukin-6 receptor) and inebilizumab (a monoclonal antibody that targets CD19 on B-cells) are also available for the treatment of aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.